Lawrence Klein, Ph.D., is Vice President of Strategy & Business Development at CRISPR Therapeutics, a biotech company based in Cambridge, MA focused on developing novel therapeutics using CRISPR gene editing technology.  His responsibilities include identifying, evaluating, and negotiating new business development opportunities, as well as managing overall corporate and portfolio strategy.  Prior to joining CRISPR Therapeutics, Dr. Klein was an Associate Partner at McKinsey & Company where he was a leader in the biotech and pharmaceutical practice, and advised clients on topics relating to corporate strategy, R&D strategy, and business development.  Dr. Klein has an academic research background in the field of T-cell immunology.